LCM
TRAW icon

Lynx1 Capital Management’s Traws Pharma TRAW Stock Holding History

Lynx1 Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.6K Buy
+15,078
New +$28.3K ﹤0.01% 23

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Lynx1 Capital Management's TRAW Position: Q1 2026 in Review

Lynx1 Capital Management opened a new position in Traws Pharma (TRAW) in Q1 2026: 15,078 shares worth $27.6K. The stake represents ﹤0.01% of the portfolio and ranks #23 among its holdings.

28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • Lynx1 Capital Management held 15,078 shares of Traws Pharma worth $27.6K as of Q1 2026.
  • Traws Pharma was a new Lynx1 Capital Management position in Q1 2026.
  • Traws Pharma made up ﹤0.01% of Lynx1 Capital Management's portfolio in Q1 2026, its #23 holding.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.